The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice

Paul Moayyedi; Alexander C. Ford; Eamonn M.M. Quigley; Amy E. Foxx-Orenstein; William D. Chey; Nicholas J. Talley; Lawrence J. Brandt

doi:10.1053/j.gastro.2009.09.077

The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice

Paul Moayyedi, Alexander C. Ford, Eamonn M.M. Quigley, Amy E. Foxx-Orenstein, William D. Chey, Nicholas J. Talley, Lawrence J. Brandt

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	789-791
Number of pages	3
Journal	Gastroenterology
Volume	138
Issue number	2
DOIs	https://doi.org/10.1053/j.gastro.2009.09.077
State	Published - Feb 2010

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1053/j.gastro.2009.09.077

Cite this

@article{5961d6f9a2354bc695b00a063b64d157,

title = "The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice",

author = "Paul Moayyedi and Ford, {Alexander C.} and Quigley, {Eamonn M.M.} and Foxx-Orenstein, {Amy E.} and Chey, {William D.} and Talley, {Nicholas J.} and Brandt, {Lawrence J.}",

note = "Funding Information: Conflicts of interest Paul Moayyedi has received consulting fees from AstraZeneca; lecture fees from Abbot, Procter & Gamble, AstraZeneca, Nycomed, and Johnson & Johnson; and grant support from AstraZeneca and Axcan . Eamonn M.M. Quigley has received consulting fees from Boehringer Ingelheim, Nycomed, Reckitts Benckiser, Salix, AGI Therapeutics, Procter & Gamble, and Ironside; lecture fees from Procter & Gamble, GlaxoSmithKline, Pfizer, Janssen-Cilag, Novartis, Norgine, Danone, and Yakult; and grant support from Procter & Gamble , Pfizer , Alimentary Health , and AGI Therapeutics . He also has equity ownership/stock options in Alimentary Health. Amy E. Foxx–Orenstein, has received consulting fees from Novartis, GlaxoSmithKline, Salix, Easton Associates, MGI Pharma, AstraZeneca, Salix, TAP, Prometheus, and Strategic Consultants; and grant support from Novartis and Salix . William D. Chey has received consulting fess from AGI, Novartis, Procter & Gamble, Salix, Takeda, and Prometheus; and lecture fees from Novartis, Procter & Gamble, Salix, Takeda, and Prometheus. Nicholas J. Talley has received consulting fees from AccreditEd, Addex Pharmaceuticals, SA, the Annenberg Center, Astellas Pharma US, AstraZeneca R&D Lund, Axcan Pharma, Conexus, Dyogen, the F Network, Medscape from WebMD, Metabolic Pharma, MGI Pharma, Microbia, Novartis, Oakstone Publishing, Optum HC, Procter & Gamble, Salix, and SK Life Science. He also holds a patent for Talley BDQ. The remaining authors disclose no conflicts. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2010",

month = feb,

doi = "10.1053/j.gastro.2009.09.077",

language = "English (US)",

volume = "138",

pages = "789--791",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - The American College of Gastroenterology Irritable Bowel Syndrome Monograph

T2 - Translating Systematic Review Data to Clinical Practice

AU - Moayyedi, Paul

AU - Ford, Alexander C.

AU - Quigley, Eamonn M.M.

AU - Foxx-Orenstein, Amy E.

AU - Chey, William D.

AU - Talley, Nicholas J.

AU - Brandt, Lawrence J.

N1 - Funding Information: Conflicts of interest Paul Moayyedi has received consulting fees from AstraZeneca; lecture fees from Abbot, Procter & Gamble, AstraZeneca, Nycomed, and Johnson & Johnson; and grant support from AstraZeneca and Axcan . Eamonn M.M. Quigley has received consulting fees from Boehringer Ingelheim, Nycomed, Reckitts Benckiser, Salix, AGI Therapeutics, Procter & Gamble, and Ironside; lecture fees from Procter & Gamble, GlaxoSmithKline, Pfizer, Janssen-Cilag, Novartis, Norgine, Danone, and Yakult; and grant support from Procter & Gamble , Pfizer , Alimentary Health , and AGI Therapeutics . He also has equity ownership/stock options in Alimentary Health. Amy E. Foxx–Orenstein, has received consulting fees from Novartis, GlaxoSmithKline, Salix, Easton Associates, MGI Pharma, AstraZeneca, Salix, TAP, Prometheus, and Strategic Consultants; and grant support from Novartis and Salix . William D. Chey has received consulting fess from AGI, Novartis, Procter & Gamble, Salix, Takeda, and Prometheus; and lecture fees from Novartis, Procter & Gamble, Salix, Takeda, and Prometheus. Nicholas J. Talley has received consulting fees from AccreditEd, Addex Pharmaceuticals, SA, the Annenberg Center, Astellas Pharma US, AstraZeneca R&D Lund, Axcan Pharma, Conexus, Dyogen, the F Network, Medscape from WebMD, Metabolic Pharma, MGI Pharma, Microbia, Novartis, Oakstone Publishing, Optum HC, Procter & Gamble, Salix, and SK Life Science. He also holds a patent for Talley BDQ. The remaining authors disclose no conflicts. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2010/2

Y1 - 2010/2

UR - http://www.scopus.com/inward/record.url?scp=75149120507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149120507&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2009.09.077

DO - 10.1053/j.gastro.2009.09.077

M3 - Letter

C2 - 20026445

AN - SCOPUS:75149120507

SN - 0016-5085

VL - 138

SP - 789

EP - 791

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -

The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this